CorMedix Reports Strong Q4 and Full-Year 2025 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 05 2026
0mins
Should l Buy CRMD?
Source: Newsfilter
- Q4 Revenue Surge: CorMedix reported net revenue of $128.6 million for Q4 2025, primarily driven by continued utilization of DefenCath among outpatient dialysis customers, with sales reaching $91.2 million, indicating strong market demand and product acceptance.
- Significant Annual Performance: Total revenue for 2025 was $311.7 million, a substantial increase from 2024, and with the acquisition of Melinta, pro forma total revenue is projected to reach $401.3 million, reflecting the company's success in expanding its product portfolio.
- Improved Profitability: The company achieved a net income of $14.0 million in Q4, with adjusted EBITDA of $77.2 million, demonstrating effective cost control and operational efficiency despite a 182% year-over-year increase in operating expenses.
- Positive Future Outlook: CorMedix reiterated its guidance for 2026, expecting net revenue between $300 million and $320 million and adjusted EBITDA between $100 million and $125 million, showcasing confidence in future growth, particularly with upcoming REZZAYO clinical data releases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRMD
Wall Street analysts forecast CRMD stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.920
Low
13.00
Averages
13.67
High
15.00
Current: 7.920
Low
13.00
Averages
13.67
High
15.00
About CRMD
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CorMedix to Report Q1 2026 Financial Results on May 14
- Earnings Release Schedule: CorMedix Therapeutics will announce its financial results for the first quarter ending March 31, 2026, before the market opens on May 14, 2026, which is expected to provide investors with crucial financial data and operational updates to assess the company's financial health.
- Conference Call Timing: The company will host a corporate update conference call at 8:30 AM Eastern Time on the same day, allowing investors to participate by calling domestic number 1-844-676-2922 or international number 1-412-634-6840, aiming to enhance communication and transparency with investors.
- Company Background: CorMedix Therapeutics focuses on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions, particularly in institutional care settings in the U.S., highlighting its strategic positioning in the healthcare market.
- Infrastructure Deployment: The company has established field-based medical and commercial infrastructure in hospitals, clinics, and infusion centers, indicating its commitment to providing services in critical healthcare locations, thereby enhancing market competitiveness and customer reach.
See More
Positive Trial Results for Rezzayo Antifungal Drug
- Trial Results: Rezzayo demonstrated comparable efficacy to standard antimicrobial regimens in reducing invasive fungal infection incidence, with a 90-day fungal-free survival rate of 60.7% versus 59.0% in the standard group, indicating its potential value in high-risk patient populations.
- Market Opportunity: CorMedix estimates that the potential U.S. market opportunity for Rezzayo in preventative care exceeds $2 billion, highlighting the drug's significance in treating high-risk blood cancer patients.
- Safety and Tolerability: The trial results indicated that Rezzayo was well tolerated, with a favorable benefit/risk profile in the patient population, and fewer drug interactions and discontinuations due to toxicity, enhancing its attractiveness for clinical use.
- FDA Application Plans: CorMedix plans to meet with the U.S. FDA in the coming months and expects to file an application for Rezzayo in the second half of 2026, further advancing the drug's path to market.
See More
CorMedix Reports Positive Phase III Results for REZZAYO in Fungal Disease Prevention
- Clinical Trial Success: CorMedix's global ReSPECT trial evaluating REZZAYO for preventing invasive fungal infections in adult patients undergoing allogeneic hematopoietic stem cell transplantation achieved a fungal-free survival rate of 60.7% at Day 90, demonstrating non-inferiority to the standard antimicrobial regimen's 59.0%, thus meeting FDA and EMA primary endpoints.
- Safety Profile Assessment: The results indicated comparable efficacy against invasive infections caused by Candida, Aspergillus, and Pneumocystis, while also showing a favorable safety profile in multiple secondary endpoints, particularly with fewer treatment-emergent adverse events leading to dose reductions, interruptions, or withdrawals.
- Clear Future Plans: The company anticipates a pre-NDA submission meeting with the FDA in the coming months, followed by a target submission of a supplemental New Drug Application in the second half of 2026 based on the ReSPECT results, reflecting strong confidence in REZZAYO's market potential.
- Positive Market Reaction: CorMedix's stock rose by 0.40% to $7.45 in pre-market trading, indicating a favorable investor response to the clinical trial results, which may enhance the company's market performance moving forward.
See More
CorMedix Announces Positive Phase III Results for REZZAYO
- Clinical Trial Success: CorMedix's ReSPECT trial demonstrated that REZZAYO achieved a 60.7% fungal-free survival rate at Day 90, comparable to the 59.0% of the standard antimicrobial regimen, indicating its efficacy and safety in high-risk patients.
- Safety Advantages: The results highlighted REZZAYO's favorable profile regarding toxicity-related discontinuations and drug-drug interactions, enhancing its potential as an alternative to standard antifungal regimens, particularly for immunocompromised patients.
- Significant Market Opportunity: CorMedix estimates that the potential U.S. market opportunity for REZZAYO in the prophylaxis of invasive fungal diseases exceeds $2 billion, reflecting substantial clinical demand and potential revenue.
- Future Development Plans: The company plans to submit a supplemental New Drug Application (sNDA) to the FDA in the second half of 2026, further advancing REZZAYO's market access and underscoring its strategic importance in antifungal therapy.
See More
CorMedix to Participate in Needham Conference
- Management Participation: CorMedix Therapeutics' senior management will engage in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, aiming to enhance investor interaction and boost company visibility.
- Product Line Expansion: The company is commercializing DefenCath® for preventing catheter-related bloodstream infections in adult patients undergoing hemodialysis, while also promoting a portfolio of anti-infective products, including MINOCIN® and REZZAYO®, to meet market demand.
- Clinical Research Progress: CorMedix is conducting clinical studies for DefenCath in Total Parenteral Nutrition and pediatric dialysis populations, indicating the company's potential for expansion into new areas, which is expected to support future product line growth.
- REZZAYO Study Results: REZZAYO is currently approved for treating candidemia and invasive candidiasis in adults, with topline results from its prophylactic study for adult patients undergoing allogeneic BMT expected in Q2 2026, potentially driving an increase in the company's stock price.
See More
CorMedix Reports 2025 Financial Results and Guidance
- Significant Revenue Growth: CorMedix reported a net income of $14.02 million in Q4 2025, translating to $0.16 per share, a slight decrease from $13.46 million and $0.20 per share last year, while total revenue surged from $31.21 million to $128.62 million, indicating strong market performance.
- Annual Performance Reversal: For the full year 2025, the company achieved a net income of $163.06 million, or $2.04 per diluted share, a stark contrast to the previous year's net loss of $17.93 million and a loss per share of $0.30, showcasing a successful turnaround in financial health.
- Positive Future Outlook: CorMedix reiterated its 2026 net revenue guidance of $300 to $320 million, with adjusted EBITDA expected between $100 and $125 million, reflecting the company's confidence in future growth and market potential.
- Pipeline and Clinical Progress: The company is conducting clinical studies for DefenCath and plans to develop it for other patient populations, while also commercializing Melinta Therapeutics' anti-infective products, thereby enriching its product portfolio and enhancing market competitiveness.
See More
CorMedix to Report Q1 2026 Financial Results on May 14
- Earnings Release Schedule: CorMedix Therapeutics will announce its financial results for the first quarter ending March 31, 2026, before the market opens on May 14, 2026, which is expected to provide investors with crucial financial data and operational updates to assess the company's financial health.
- Conference Call Timing: The company will host a corporate update conference call at 8:30 AM Eastern Time on the same day, allowing investors to participate by calling domestic number 1-844-676-2922 or international number 1-412-634-6840, aiming to enhance communication and transparency with investors.
- Company Background: CorMedix Therapeutics focuses on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions, particularly in institutional care settings in the U.S., highlighting its strategic positioning in the healthcare market.
- Infrastructure Deployment: The company has established field-based medical and commercial infrastructure in hospitals, clinics, and infusion centers, indicating its commitment to providing services in critical healthcare locations, thereby enhancing market competitiveness and customer reach.
See More
Positive Trial Results for Rezzayo Antifungal Drug
- Trial Results: Rezzayo demonstrated comparable efficacy to standard antimicrobial regimens in reducing invasive fungal infection incidence, with a 90-day fungal-free survival rate of 60.7% versus 59.0% in the standard group, indicating its potential value in high-risk patient populations.
- Market Opportunity: CorMedix estimates that the potential U.S. market opportunity for Rezzayo in preventative care exceeds $2 billion, highlighting the drug's significance in treating high-risk blood cancer patients.
- Safety and Tolerability: The trial results indicated that Rezzayo was well tolerated, with a favorable benefit/risk profile in the patient population, and fewer drug interactions and discontinuations due to toxicity, enhancing its attractiveness for clinical use.
- FDA Application Plans: CorMedix plans to meet with the U.S. FDA in the coming months and expects to file an application for Rezzayo in the second half of 2026, further advancing the drug's path to market.
See More
CorMedix Reports Positive Phase III Results for REZZAYO in Fungal Disease Prevention
- Clinical Trial Success: CorMedix's global ReSPECT trial evaluating REZZAYO for preventing invasive fungal infections in adult patients undergoing allogeneic hematopoietic stem cell transplantation achieved a fungal-free survival rate of 60.7% at Day 90, demonstrating non-inferiority to the standard antimicrobial regimen's 59.0%, thus meeting FDA and EMA primary endpoints.
- Safety Profile Assessment: The results indicated comparable efficacy against invasive infections caused by Candida, Aspergillus, and Pneumocystis, while also showing a favorable safety profile in multiple secondary endpoints, particularly with fewer treatment-emergent adverse events leading to dose reductions, interruptions, or withdrawals.
- Clear Future Plans: The company anticipates a pre-NDA submission meeting with the FDA in the coming months, followed by a target submission of a supplemental New Drug Application in the second half of 2026 based on the ReSPECT results, reflecting strong confidence in REZZAYO's market potential.
- Positive Market Reaction: CorMedix's stock rose by 0.40% to $7.45 in pre-market trading, indicating a favorable investor response to the clinical trial results, which may enhance the company's market performance moving forward.
See More
CorMedix Announces Positive Phase III Results for REZZAYO
- Clinical Trial Success: CorMedix's ReSPECT trial demonstrated that REZZAYO achieved a 60.7% fungal-free survival rate at Day 90, comparable to the 59.0% of the standard antimicrobial regimen, indicating its efficacy and safety in high-risk patients.
- Safety Advantages: The results highlighted REZZAYO's favorable profile regarding toxicity-related discontinuations and drug-drug interactions, enhancing its potential as an alternative to standard antifungal regimens, particularly for immunocompromised patients.
- Significant Market Opportunity: CorMedix estimates that the potential U.S. market opportunity for REZZAYO in the prophylaxis of invasive fungal diseases exceeds $2 billion, reflecting substantial clinical demand and potential revenue.
- Future Development Plans: The company plans to submit a supplemental New Drug Application (sNDA) to the FDA in the second half of 2026, further advancing REZZAYO's market access and underscoring its strategic importance in antifungal therapy.
See More
CorMedix to Participate in Needham Conference
- Management Participation: CorMedix Therapeutics' senior management will engage in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, aiming to enhance investor interaction and boost company visibility.
- Product Line Expansion: The company is commercializing DefenCath® for preventing catheter-related bloodstream infections in adult patients undergoing hemodialysis, while also promoting a portfolio of anti-infective products, including MINOCIN® and REZZAYO®, to meet market demand.
- Clinical Research Progress: CorMedix is conducting clinical studies for DefenCath in Total Parenteral Nutrition and pediatric dialysis populations, indicating the company's potential for expansion into new areas, which is expected to support future product line growth.
- REZZAYO Study Results: REZZAYO is currently approved for treating candidemia and invasive candidiasis in adults, with topline results from its prophylactic study for adult patients undergoing allogeneic BMT expected in Q2 2026, potentially driving an increase in the company's stock price.
See More
CorMedix Reports 2025 Financial Results and Guidance
- Significant Revenue Growth: CorMedix reported a net income of $14.02 million in Q4 2025, translating to $0.16 per share, a slight decrease from $13.46 million and $0.20 per share last year, while total revenue surged from $31.21 million to $128.62 million, indicating strong market performance.
- Annual Performance Reversal: For the full year 2025, the company achieved a net income of $163.06 million, or $2.04 per diluted share, a stark contrast to the previous year's net loss of $17.93 million and a loss per share of $0.30, showcasing a successful turnaround in financial health.
- Positive Future Outlook: CorMedix reiterated its 2026 net revenue guidance of $300 to $320 million, with adjusted EBITDA expected between $100 and $125 million, reflecting the company's confidence in future growth and market potential.
- Pipeline and Clinical Progress: The company is conducting clinical studies for DefenCath and plans to develop it for other patient populations, while also commercializing Melinta Therapeutics' anti-infective products, thereby enriching its product portfolio and enhancing market competitiveness.
See More
